Gonorrhea – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Gonorrhea – Pipeline Review, H2 2019’, provides an overview of the Gonorrhea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gonorrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gonorrhea and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Gonorrhea

– The report reviews pipeline therapeutics for Gonorrhea by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Gonorrhea therapeutics and enlists all their major and minor projects

– The report assesses Gonorrhea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Gonorrhea

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Gonorrhea

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Gonorrhea pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Biolytics Pharma

Debiopharm International SA

Entasis Therapeutics Inc

Evofem Biosciences Inc

GlaxoSmithKline Plc

Hsiri Therapeutics LLC

Melinta Therapeutics Inc

Merck & Co Inc

Microbiotix Inc

Paratek Pharmaceuticals Inc

Pharmiva AB

Redx Pharma Plc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Gonorrhea ”“ Overview

Gonorrhea ”“ Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Gonorrhea ”“ Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gonorrhea ”“ Companies Involved in Therapeutics Development

Biolytics Pharma

Debiopharm International SA

Entasis Therapeutics Inc

Evofem Biosciences Inc

GlaxoSmithKline Plc

Hsiri Therapeutics LLC

Melinta Therapeutics Inc

Merck & Co Inc

Microbiotix Inc

Paratek Pharmaceuticals Inc

Pharmiva AB

Redx Pharma Plc

Gonorrhea ”“ Drug Profiles

Amphora ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BCP-1 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic for Gonorrhea ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Debio-1453 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

edodekin alfa SR ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein for Gonorrhea ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gepotidacin mesylate ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gonorrhea vaccine ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KKL-35 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MBX-4132 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NGoXIM ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omadacycline tosylate ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-002 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PEG-2S ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PPCM ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RXP-2382 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Bacterial Infections ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit 16S rRNA for Gonorrhea and Chlamydia Infections ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DNA Gyrase and Topoisomerase IV for Gonorrhea ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PBP2 for Gonorrhea ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Tubulin for Gonorrhea and Oncology ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zoliflodacin ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gonorrhea ”“ Dormant Projects

Gonorrhea ”“ Discontinued Products

Gonorrhea ”“ Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Gonorrhea, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Gonorrhea ”“ Pipeline by Biolytics Pharma, H2 2019

Gonorrhea ”“ Pipeline by Debiopharm International SA, H2 2019

Gonorrhea ”“ Pipeline by Entasis Therapeutics Inc, H2 2019

Gonorrhea ”“ Pipeline by Evofem Biosciences Inc, H2 2019

Gonorrhea ”“ Pipeline by GlaxoSmithKline Plc, H2 2019

Gonorrhea ”“ Pipeline by Hsiri Therapeutics LLC, H2 2019

Gonorrhea ”“ Pipeline by Melinta Therapeutics Inc, H2 2019

Gonorrhea ”“ Pipeline by Merck & Co Inc, H2 2019

Gonorrhea ”“ Pipeline by Microbiotix Inc, H2 2019

Gonorrhea ”“ Pipeline by Paratek Pharmaceuticals Inc, H2 2019

Gonorrhea ”“ Pipeline by Pharmiva AB, H2 2019

Gonorrhea ”“ Pipeline by Redx Pharma Plc, H2 2019

Gonorrhea ”“ Dormant Projects, H2 2019

Gonorrhea ”“ Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development for Gonorrhea, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared